Skip to main content

08-17-2018 | Medications | Review | Article

Adjuvant Pharmacotherapies to Insulin for the Treatment of Type 1 Diabetes

Current Diabetes Reports

Authors: Mustafa Tosur, Maria J. Redondo, Sarah K. Lyons

Publisher: Springer US


Purpose of Review

Insulin therapy alone fails to achieve target glycemic control in the majority of individuals with type 1 diabetes (T1D), motivating the investigation of additive medications. This review focuses on the recent findings on the use of adjunctive pharmacotherapy in T1D.

Recent Findings

Metformin and glucagon-like peptide-1 receptor agonists have been associated with weight reduction and decrease in daily insulin requirements without sustainable improvement in glycemic control. Sodium-glucose cotransporter (SGLT)-2 inhibitors, dual SGLT-1/2 inhibitors, and pramlintide have been shown to reduce hemoglobin A1c, induce weight loss, and lower insulin dose. The benefits of dipeptidyl peptidase-4 inhibitors, thiazolidinediones, and alpha glucosidase inhibitors appear to be more limited. Gastrointestinal symptoms and increased hypoglycemia are adverse effects of certain classes.


Although not devoid of side effects, additive pharmacotherapies in T1D can improve glycemic control and lower body weight and insulin requirement. Longer studies are needed before consideration for widespread clinical care.

Please log in to get access to this content

Related topics

Virtual EASD Annual Meeting 2020 coverage

Get the latest news and expert commentary now.

Why psychosocial care matters

Clinical experts from the fields of diabetes and psychology address the issues in a new series of interviews.

  • » This content has been endorsed by the PSAD, EASD and ACBRD.
Image Credits